06/14/2024
In the realm of drug development, the industry puts a great deal of emphasis on centering the patient experience. As a result, it is imperative that drug developers consider how they translate scientific and medical knowledge into actionable insights that support the patient journey. To delve deeper into this topic, Pharmaceutical Executive sat down with Gabi Hanna, Co-Founder and CEO of Lamassu Pharma, to talk about the company’s beginnings, as well as its novel small molecule MDM2 inhibitor that activates P53 to control cancer growth.
CLICK HERE to read Pharma Exec‘s Q&A with Lamassu Biotech CEO Dr. Gabi Hanna.